The company's providers page describes its clinicians as employed by the company, though the terms of use contain separate language about third-party providers
Why Trusting the Process Matters Weight loss is a deeply personal and often emotional experience
Patients receiving compounded versions are extrapolating clinical evidence from STEP-1 (Wegovys pivotal trial), which showed average weight loss of 14.9% over 68 weeks at the 2.4 mg dose
It is not approved for human use as a therapeutic compound and is not for human consumption or injection
Kosiborod MN, Abildstrm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Mller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC
The GLP-1 agonists are also being investigated for efficacy in neurodegenerative diseases including Alzheimers and Parkinsons diseases [28]